Financial Data and Key Metrics Changes - Neogen reported revenue of approximately $209 million for Q1 FY 2026, reflecting a year-over-year increase of 0.3% on a core basis [12][15] - Adjusted EBITDA was $35.5 million, representing a margin of 17%, impacted by lower revenue, higher tariff costs, and increased operating expenses [21][22] - Free cash flow for the quarter was an outflow of $13 million, an improvement of $43 million compared to the prior year [22][23] Business Line Data and Key Metrics Changes - Food safety segment revenues were $152 million, down 4.6% year-over-year, with a core decline of 1.7% [15][16] - Animal safety segment revenues were $57 million, a decline of 0.8%, but core revenue grew by 5.8% [17] - Petrifilm experienced a mid-single-digit decline in revenue, attributed to distributor inventory adjustments rather than a change in underlying demand [12][16] Market Data and Key Metrics Changes - Core revenue growth was mixed across regions, with LATAM showing mid-single-digit growth, while the U.S. and Canada had low single-digit growth [18] - The APAC region faced challenges, particularly in China and ASEAN countries, impacting overall performance [19] Company Strategy and Development Direction - The company aims to drive top-line growth, right-size its cost base, and reinvigorate innovation without a major strategic overhaul [5][7] - A focus on optimizing the product portfolio for market share gains and profitability, including targeted price increases, is underway [8] - The addition of a Chief Commercial Officer is being pursued to enhance global commercial leadership [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's potential for growth despite current execution challenges, emphasizing the need for improved operational efficiency [4][29] - The CEO highlighted the importance of regaining market share and improving customer relationships as key priorities moving forward [26][39] Other Important Information - The company executed a global headcount reduction of approximately 10%, aiming for annualized savings of about $20 million [7][24] - The divestiture of the cleaners and disinfectants business generated approximately $115 million in net proceeds, which was used to pay down debt [22] Q&A Session Summary Question: Can you discuss the strengths of Neogen and the challenges faced? - The CEO confirmed the company's strong market position and employee dedication, while acknowledging execution challenges that have led to market share losses [33][34] Question: How will the company regain market share with unique products? - The CEO outlined three strategies: leveraging a broad product portfolio, exploring underpenetrated markets, and enhancing execution within the commercial organization [38][39] Question: What is the expected progression of EBITDA margins throughout the year? - The CFO indicated that EBITDA margins are expected to improve as the year progresses, driven by volume increases and cost structure benefits [40] Question: What is the timeline for outlining the company's vision post-CEO transition? - The CEO mentioned that more details on the company's vision will be shared in early 2026, focusing on quick wins and critical projects [44] Question: Can you clarify the $6 million in sample collection costs? - The CFO explained that these costs are related to scrap and quality flags, indicating that the company is currently selling the product at a loss [72] Question: How will the company manage headcount and turnover during this transition? - The CEO emphasized the need for continuous evaluation of resources and the importance of re-engaging employees to drive growth [76][77] Question: Will there be additional divestitures beyond the genomics process? - The CEO confirmed that the company is always in portfolio review mode and will continue to assess product lines for optimization [85][87]

Financial Performance - Neogen's Q1 FY26 revenue was $209.2 million, a decrease from $217.0 million in Q1 FY25[13] - Adjusted EBITDA for Q1 FY26 was $35.5 million, compared to $43.7 million in Q1 FY25, with a margin of 17.0% versus 20.1%[14] - Adjusted Net Income decreased to $9.4 million ($0.04 per share) in Q1 FY26 from $14.4 million ($0.07 per share) in Q1 FY25[15] - Core revenue growth in Food Safety segment was (1.7)%, while Animal Safety segment saw a core revenue growth of 5.8%[17] - The company's gross debt stands at $800 million, with net debt at $661 million[19] - Q1 Free Cash Flow improved by $43 million compared to the prior year[21] Strategic Initiatives and Outlook - A cost-reduction initiative is expected to yield annualized savings of $20 million[11] - The divestiture of Cleaners & Disinfectants funded a $100 million debt paydown[11] - The company reaffirms its full-year outlook with revenue projected between $820 million and $840 million and Adjusted EBITDA between $165 million and $175 million[11, 24] - A headcount reduction of approximately 10% has been implemented to align with the current operating environment[23]

Financial Data and Key Metrics Changes - The fourth quarter revenues were $225 million, with core revenue down 2.9% for the quarter, impacted by foreign currency and discontinued products [19] - Gross margin in Q4 was 41.2%, affected by lower volume, elevated inventory write-offs, and production inefficiencies [23][24] - Adjusted net income for Q4 was $11 million, down from $22 million in the prior year quarter, primarily due to lower adjusted EBITDA [26] Business Line Data and Key Metrics Changes - Food Safety segment revenues were $162 million in Q4, down 3% year-over-year, with a core revenue decline of 1.3% [19] - Animal Safety segment revenues were $64 million, including a core revenue decline of 6.7% compared to the prior year quarter [20] - Genomics core revenue declined low single digits in Q4, reflecting a sequential improvement [20] Market Data and Key Metrics Changes - Core revenue growth in Europe was up mid single digits, while Asia Pacific was down mid single digits [21] - Latin America region saw a mid single digit decline on a core basis, with growth in some product lines offset by declines in others [22] - U.S. and Canada region experienced low single digit growth in food safety core revenue [22] Company Strategy and Development Direction - The company is focused on improving internal processes and managing through current market conditions to capitalize on future opportunities [17] - A targeted improvement plan has been released to manage the transition period effectively [17] - The company is prioritizing pathogen detection and has launched new products to enhance its offerings in the food safety market [10][19] Management's Comments on Operating Environment and Future Outlook - Management noted that end market conditions have worsened, particularly in food safety, due to inflation pressures on food producers [4][5] - The expectation is for revenue in fiscal 2026 to be between $820 million and $840 million, reflecting ongoing market challenges [29] - Management anticipates that gross margin will face headwinds from sample collection and tariffs, but expects improvements in the second half of the fiscal year [30] Other Important Information - The company completed the divestiture of its cleaners and disinfectants business, resulting in approximately $115 million in net proceeds [27] - Free cash flow in Q4 was roughly breakeven, with total capital expenditures declining to $16 million [28] - The company has successfully remediated two Sarbanes-Oxley material weaknesses [31] Q&A Session Summary Question: Why is this the right time to put out guidance with a new CEO? - Management indicated that the guidance reflects a business-as-usual approach and is intended to provide clarity on the upcoming year [37][38] Question: How much of a headwind is built for next year regarding tariffs? - Management confirmed that the $10 million tariff impact is the expected headwind for fiscal 2026 [41] Question: How does the company plan to grow above market despite consumer pressures? - Management highlighted regulatory opportunities and increased testing focus as key growth drivers [44][45] Question: What are the expectations for food safety industry growth? - Management expects food safety testing to grow at a lower rate than historical mid-single digits due to current market conditions [53][54] Question: What is the expected impact of divestitures on operating expenses? - Management noted that most costs associated with divested businesses will go directly with those businesses, with minimal stranded costs remaining [59][60]

Financial Performance - Q4 FY25 revenue was $225.5 million, a decrease from $236.8 million in Q4 FY24[11] - Adjusted EBITDA for Q4 FY25 was $40.6 million, compared to $53.0 million in Q4 FY24, with a margin of 18.0% versus 22.4%[12] - Adjusted net income decreased to $11.3 million ($0.05 per share) in Q4 FY25 from $22.4 million ($0.10 per share) in Q4 FY24[13] - Core revenue growth in the Food Safety segment was (1.3)%, while the Animal Safety segment experienced a core revenue growth of (6.7)%[15] Balance Sheet and Capital Allocation - As of May 31, 2025, gross debt was $900 million and net debt was $771 million[17] - Pro forma net debt, after accounting for cash and equivalents, is $656 million with gross debt at $800 million[17] - Net proceeds from the Cleaners & Disinfectants divestiture were approximately $115 million, with $100 million allocated for debt paydown in Q1[19] FY26 Outlook - The company anticipates FY26 revenue to be between $820 million and $840 million[21] - Adjusted EBITDA is projected to be in the range of $165 million to $175 million[21] - Capital expenditures are estimated to be around $50 million, including approximately $35 million for integration-related expenses[21]